At Flora Growth, we’re building the world’s largest and lowest-cost vertically-integrated producer of organic cannabis oils and medical and consumer products, focused on transforming the cannabis industry.
We’re working to be the lowest cost producer in the world at approximately US$0.18 per gram of flower.
$57 million ($107 million post-money valuation based on the fully subscribed offering and exercising of issued warrants)
The minimum investment amount is $1,200 / 1600 units
Each Unit contains one-half of one common share purchase warrant. Each whole warrant can be exercised at a price of $1.00 for one Flora common share.
Unit Offering at a price of $0.75 per Unit. Each Unit is comprised of one Flora common share and one-half of one common share purchase warrant
Click below to take a tour through our beautiful farm in Giron (Bucaramanga), Colombia where we cultivate the raw material that forms the foundation of all our products.
We’re working to supply the worldwide pharmaceutical, cosmetic and food and beverage industries with the highest-quality Organic CBD oils and derivatives in the market. As a vertically-integrated company, we’ll use our organic CBD-oil to supply our beauty and cosmetics division, We also have letters of intent with several companies that want to use our CBD-oil for infusion into their juices, coffees, creams, lotions, capsules and panela, a popular sweetener in South America.
We strategically chose Giron (Bucaramanga), Colombia as the hub for our cannabis operations because of the region’s ideal conditions for growing cannabis outdoors. There are no seasons with 12 hours of natural daylight, high-quality soil, natural spring water deposits on site and a light constant wind that decreases the incidence of plant-harming pathogens!
Colombia has an attractive regulatory environment for cannabis and foreign investment. Colombia is an active player in the global market with an open free market economy that has many free trade agreements (FTAs) worldwide, including with the United States, Canada, European Union and is a founding member of the Pacific Alliance Regional trade block.
Colombia is amongst the largest global suppliers of agriculture products including cut flower, coffee beans and bananas.
Flora’s cannabis operations are located in the Department of Santander, a stable, secure region, with low-unemployment.
In terms of distribution networks, we have a strategic partnership with the Ramirez family. They’re the largest citrus producer in Colombia, exporting to the US and Europe. Working with them gives us gives us access to over 2,180 points of sale throughout Colombia as well as exporting channels. We’ve also signed a term sheet with Rappi, leading Latin American on-demand delivery company to offer our products on Rappi’s virtual platform. Rappi has over 100,000 couriers across Latin America and 13 million users.
Flora is fully licensed and based out of Giron, Colombia where we plan on cultivating 100 hectares of cannabis (1 hectare = 2.47 acres). Flora has acquired the rights to an additional 2,132 hectares in Puerto Boyaca to increase the size of its cultivation as the market demand for Flora’s products increases.
Flora Beauty, Our beauty abd cosmetics division, will produce nine different beauty and cosmetics products under two beauty brands. Flora has also signed letters of intent to aquire two revenue-genrating companies with significant growth potential.
"Flora Beuty", will produce nine different beauty and cosmetic products via a high-end product line called "Mind" and a mass-market product line called "Elements" using Flora's organic CBD oil.
Flora has agreed to aquire Kasa Wholefoods Company S.A.S., a Colombian com[any which produces exotic fruit juice, chocolates and other confectionary. Through Kasa, Flora intends to work with the Colombian regulatory authorities to produce CBD infused food and beverages.
Flora has also agreed to acquire Cronomed, a leeding pharmaceutical company in Colombia. Cronomed produces medical products, dietary supplements, nutritional supplements and cosmetics. All of Cronomed's products are registered and have been approved by the INVIMA (FDA-equivalent). Flora will work with Cronomed's existing R&D team to explore how Cronomed's product line can incorporate Flora's organic-CBD oil to improve the effectiveness of these products.
Our experienced management team and board of directors has successfully led Flora’s rapid growth in Latin America and has a proven track record of building and developing world-class revenue generating businesses.
CEO & Director
VP Corp. Development
William Connell Steers
Initially, we intend to service the domestic Colombian market and certain countries in Latin America that have legalized medicinal cannabis and allow for the importation of CBD-based products. Presently, Argentina, Chile, Ecuador, Uruguay and Peru allow the importation of CBD-based products. We have commenced discussions with potential partners and customers in these jurisdictions, and we expect to export to these countries during 2020.
Population: 650 million
GDP: US$5.3 trillion
Total Health Expenditures: US$354 billion
Total Pharmaceutical Expenditure (2016):US$117 billion
Estimated Total of Cannabis Users: 5.4%
Estimated Cannabis Market Value (2018): US$12.7 billion
Estimated Medical Cannabis Market Value (2028): US$8.5 billion
Estimated Rec Cannabis Market Value (2028): US$4.2 billion
Charlotte’s Web Holdings (CBWF), based on the Hemp Industry Daily, projects the CBD market at $6.1-7.5Bn by 2023
BDS Analytics projects the market at $20Bn by 2024
The Brightfield Group, an industry consultancy, projects the U.S. CBD market at $23Bn by 2023
Green Growth Brands projects the CBD Beauty market (beauty plus personal care) at $13Bn by 2024; $25Bn by 2029
Based on feedback from the companies, broker estimates range from $12-46Bn by 2025
Click get started below to begin Your investment in Flora Growth
Questions? Check out our Frequently Asked Question section here.
The offering will be made only by means of an offering circular. An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement which only means that Flora Growth Corp. may make sales of the securities described by that offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. The securities offered by Flora Growth Corp. are highly speculative. Investing in shares of common stock of Flora Growth Corp. involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. You may obtain a copy of the Form 1-A offering circular that is part of said offering statement HERE and the supplment filing HERE. You should read the offering circular before making any investment.
The offering materials may contain forward-looking statements and information relating to, among other things, Flora Growth Corp. its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company's management. When used in the offering materials, the words "estimate," "project," "believe," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements, which constitute forward-looking statements. These statements reflect management's current views with respect to future events and are subject to risks and uncertainties that could cause Flora Growth Corp. actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. Flora Growth Corp. does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.